Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40273-017-0502-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on Real-world Efficacy and Toxicity Analysis of Abiraterone Acetate versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer in Asian Patients.
Clin Genitourin Cancer
October 2024
Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Tamil Nadu, India. Electronic address:
Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
JAMA Oncol
July 2024
Genito Urinary Cancer Research Group, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Article Synopsis
- Cardiovascular events are a major cause of death in men with advanced prostate cancer, and new treatments like androgen receptor signaling inhibitors (ARSI) may have unknown cardiovascular side effects.
- The study aims to evaluate how the addition of ARSI affects the incidence of cardiovascular events in patients with locally advanced and metastatic prostate cancer.
- A systematic review of 24 studies found that ARSI therapy significantly increases the risk of cardiovascular events, with a risk ratio indicating a higher incidence of both all-grade and severe cardiovascular issues.
Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.
Eur Urol
June 2024
The Christie and Salford Royal Hospital NHS Foundation Trusts and University of Manchester, Manchester, UK.
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer.
Lancet Oncol
October 2023
Department of Urology, La Croix du Sud Hospital, Toulouse, France; Department of Urology, Institut Universitaire du Cancer Toulouse-Oncopôle, Toulouse, France.
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
Eur Urol
January 2024
GRC 5 Predictive Onco-Uro, Sorbonne University, Department of Urology, Pitie-Salpetriere Hospital, AP-HP, Paris, France. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!